Sensitization of multiple myeloma and B lymphoma lines to dexamethasone and γ-radiation-induced apoptosis by CD40 activation

Apoptosis

Volumn 10, Issue 1, 2005, Pages 123-134

  Zhou, Zhao Hua ^a   Shi, Qin ^a   Wang, Jiang Fang ^a   Chen, Yong Jing ^a   Zhuang, Yu Mei ^a   Pan, Jian Zhong ^a   Xu, Chang Shao ^a   Qi, Chun Jian ^a   Zhang, Xue Guang ^a  

^a SOOCHOW UNIVERSITY   (China)

Author keywords

radiation; CD40 activation; Dexamethasone; Lymphoma; Myeloma

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND MONOCLONAL ANTIBODY; DEXAMETHASONE; INTERLEUKIN 6; MESSENGER RNA; PROTEIN BAX; PROTEIN BCL XL;

APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL ACTIVATION; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DAUDI CELL; DRUG SENSITIVITY; DRUG SENSITIZATION; GAMMA RADIATION; HUMAN; HUMAN CELL; LYMPHOMA CELL LINE; MESSENGER RNA SYNTHESIS; MULTIPLE MYELOMA; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ANTIGENS, CD40; ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; CELL LINE, TUMOR; DEXAMETHASONE; GAMMA RAYS; HUMANS; LYMPHOMA, B-CELL; MULTIPLE MYELOMA;

EID: 17644401687     PISSN: 13608185     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10495-005-6067-6     Document Type: Article

References (40)

1. Jaffe ES, Sander CA, Flaig MJ. Cutaneous lymphomas: A proposal for a unified approach to classification using the R.E.A.L./WHO Classification. Ann Oncol 2000; 11 (Suppl 1): 17-21.
2. Kim H. Composite lymphoma and related disorders. Am J Clin Pathol 1993; 99: 445-451.
3. Epstein J. Myeloma phenotype: Clues to disease origin and manifestation. Hematol Oncol Clin North Am 1992; 6: 249-256.
4. Sarris AH, Braunschweig I, Medeiros LJ, et al. Primary cutaneous non-Hodgkin's lymphoma of Ann Arbor stage I: Preferential cutaneous relapses but high cure rate with doxorubicin-based therapy. J Clin Oncol 2001; 19: 398-405.
5. Behr TM, Griesinger F, Riggert J, et al. High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Results of a pilot study. Cancer 2002; 94: 1363-1372.
6. Wiseman GA, Leigh B, Erwin WD, et al. Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma. Cancer 2002; 94: 1349-1357.
7. Choudhury BA, Liang JC, Thomas EK, et al. Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses. Blood 1999; 93: 780-786.
8. Buhmann R, Nolte A, Westhaus D, Emmerich B, Hallek M. CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: Stimulation of allogeneic versus autologous T cells generates different types of effector cells. Blood 1999; 93: 1992-2002.
9. Tong AW, Stone MJ. Prospects for CD40-directed experimental therapy of human cancer. Cancer Gene Ther 2003; 10: 1-13.
10. Pellat-Deceunynck C, Amiot M, Robillard N, Wijdenes J, Bataille R. CD11a-CD18 and CD102 interactions mediate human myeloma cell growth arrest induced by CD40 stimulation. Cancer Res 1996; 56: 1909-1916.
11. Hirano A, Longo DL, Taub DD, et al. Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand. Blood 1999; 93: 2999-3007.
12. Jacquy C, Delepaut B, Van Daele S, et al. A prospective study of minimal residual disease in childhood B-lineage acute lymphoblastic leukaemia: MRD level at the end of induction is a strong predictive factor of relapse. Br J Haematol 1997; 98: 140-146.
13. Farahat N, Morilla A, Owusu-Ankomah K, et al. Detection of minimal residual disease in B-lineage acute lymphoblastic leukaemia by quantitative flow cytometry. Br J Haematol 1998; 101: 158-164.
14. Scholten C, Fodinger M, Mitterbauer M, et al. Kinetics of minimal residual disease during induction/consolidation therapy in standard-risk adult B-lineage acute lymphoblastic leukemia. Ann Hematol 1995; 71: 155-160.
15. Younes A, Kadin ME. Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy. J Clin Oncol 2003; 21: 3526-3534.
16. Hayashi T, Treon SP, Hideshima T, et al. Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells. Br J Haematol 2003; 121: 592-596.
17. Zhou ZH, Wang JF, Wang YD, et al. An agonist anti-human CD40 monoclonal antibody that induces dendritic cell formation and maturation and inhibits proliferation of a myeloma cell line. Hybridoma 1999; 18: 471-478.
18. Zhang XG, Gaillard JP, Robillard N, et al. Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood 1994; 83: 3654-3663.
19. Tong AW, Lee JC, Wang RM, Ordonez G, Stone MJ. Augmentation of lymphokine-activated killer cell cytotoxicity by monoclonal antibodies against human small cell lung carcinoma. Cancer Res 1989; 49: 4103-4108.
20. Ferlin-Bezombes M, Jourdan M, Liautard J, Brochier J, Rossi JF, Klein B. IFN-alpha is a survival factor for human myeloma cells and reduces dexamethasone-induced apoptosis. J Immunol 1998; 161: 2692-2699.
21. Bjorck P, Axelsson B, Paulie S. Expression of CD40 and CD43 during activation of human B lymphocytes. Scand J Immunol 1991; 33: 211-218.
22. Westendorf JJ, Ahmann GJ, Armitage RJ, et al. CD40 expression in malignant plasma cells. Role in stimulation of autocrine IL-6 secretion by a human myeloma cell line. J Immunol 1994; 152: 117-128.
23. Costello RT, Gastaut JA, Olive D. Whatis the real role of CD40 in cancer immunotherapy? Immunol Today 1999; 20: 488-493.
24. Funakoshi S, Longo DL, Beckwith M, et al. Inhibition of human B-cell lymphoma growth by CD40 stimulation. Blood 1994; 83: 2787-2794.
25. Vairo G, Innes KM, Adams JM. Bcl-2 has a cell cycle inhibitory function separable from its enhancement of cell survival. Oncogene 1996; 13: 1511-1519.
26. Eliopoulos AG, Dawson CW, Mosialos G, et al. CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr Virus-encoded LMP1: Involvement of TRAF3 as a common mediator. Oncogene 1996; 13: 2243-2254.
27. Gallagher NJ, Eliopoulos AG, Agathangelo A, Oates J, Crocker J, Young LS. CD40 activation in epithelial ovarian carcinoma cells modulates growth, apoptosis, and cytokine secretion. Mol Pathol 2002; 55: 110-120.
28. Voorzanger-Rousselot N, Favrot M, Blay JY. Resistance to cytotoxic chemotherapy induced by CD40 ligand in lymphoma cells. Blood 1998; 92: 3381-3387.
29. Evan G, Littlewood T. A matter of life and cell death. Science 1998; 281: 1317-1322.
30. Harada H, Grant S. Apoptosis regulators. Rev Clin Exp Hematol 2003; 7: 117-138.
31. O'Reilly LA, Huang DC, Strasser A. The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry. Embo J 1996; 15: 6979-6990.
32. Chao DT, Korsmeyer SJ. BCL-2 family: Regulators of cell death. Annu Rev Immunol 1998; 16: 395-419.
33. Ruvolo PP, Deng X, May WS. Phosphorylation of Bcl2 and regulation of apoptosis. Leukemia 2001; 15: 515-522.
34. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74: 609-619.
35. Chao DT, Linette GP, Boise LH, White LS, Thompson CB, Korsmeyer SJ. Bcl-XL, and Bcl-2 repress a common pathway of cell death. J Exp Med 1995; 182: 821-828.
36. Borovitskaya AE, Evtushenko VI, Sabol SL. Gamma-radiation-induced cell death in the fetal rat brain possesses molecular characteristics of apoptosis and is associated with specific messenger RNA elevations. Brain Res Mol Brain Res 1996; 35: 19-30.
37. Rothstein TL, Wang JK, Panka DJ, et al. Protection against Fas-dependent Th1-mediated apoptosis by antigen receptor engagement in B cells. Nature 1995; 374: 163-165.
38. Bergamo A, Bataille R, Pellat-Deceunynck C. CD40 and CD95 induce programmed cell death in the human myeloma cell line XG2. Br J Haematol 1997; 97: 652-655.
39. Morimoto H, Yonehara S, Bonavida B. Overcoming tumor necrosis factor and drug resistance of human tumor cell lines by combination treatment with anti-Fas antibody and drugs or toxins. Cancer Res 1993; 53: 2591-2596.
40. Afford SC, Randhawa S, Eliopoulos AG, Hubscher SG, Young LS, Adams DH. CD40 activation induces apoptosis in cultured human hepatocytes via induction of cell surface fas ligand expression and amplifies fas-mediated hepatocyte death during allograft rejection. J Exp Med 1999; 189: 441-446.